Prothena (Prothena) Additional Paid-In Capital : $1,554.13 Mil(As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Prothena Additional Paid-In Capital?

Prothena's quarterly additional paid-in capital increased from Sep. 2023 ($1,529.25 Mil) to Dec. 2023 ($1,540.86 Mil) and increased from Dec. 2023 ($1,540.86 Mil) to Mar. 2024 ($1,554.13 Mil).

Prothena's annual additional paid-in capital increased from Dec. 2021 ($1,181.63 Mil) to Dec. 2022 ($1,454.52 Mil) and increased from Dec. 2022 ($1,454.52 Mil) to Dec. 2023 ($1,540.86 Mil).

Prothena Additional Paid-In Capital Historical Data

The historical data trend for Prothena's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prothena Additional Paid-In Capital Chart

Prothena Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

944.41

966.64

1,181.63

1,454.52

1,540.86

Prothena Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															1,486.75	1,515.61	1,529.25	1,540.86	1,554.13

Prothena Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Prothena Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Prothena's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Prothena (Prothena) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prothena Corp PLC (NAS:PRTA) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

0PT:Germany

Address

77 Sir John Rogerson’s Quay, Block C, Grand Canal Docklands, Dublin 2, IRL, D02 VK60

Website

https://www.prothena.com

Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Executives

Karin L Walker	officer: See Remarks	C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Brandon S. Smith	officer: Chief Operating Officer	C/O PROTHENA BIOSCIENCES INC., 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Carol D. Karp	officer: Chief Regulatory Officer	C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Michael J Malecek	officer: Chief Legal Officer	C/O PROTHENA BIOSCIENCES, INC., 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Hideki Garren	officer: Chief Medical Officer	C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Wagner M. Zago	officer: Chief Scientific Officer	C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Dennis J. Selkoe	director	650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Helen Susan Kim	director	3832 BAY CENTER PLACE, HAYWARD CA 94545
Tran Nguyen	officer: Chief Financial Officer	C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Gene G. Kinney	officer: CSO & Head of R&D	C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Dunn William H. Jr.	director	C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Shane Cooke	director	TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000
Richard T Collier	director
Lars Ekman	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Paula K Cobb	director	NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453